As to a disease-specific therapy for Fabry disease, enzyme replacement therapy (ERT) with recombinant α-Gals (agalsidase alfa produced in human fibroblasts and agalsidase beta expressed in Chinese hamster ovary cells) has been successfully used [2, 3]. The gene discussed is GLA; the disease is Fabry disease.